ライフサイエンスコーパス: infective endocarditis

1 the appropriate management and treatment of infective endocarditis.

2 uggests novel therapeutic options to prevent infective endocarditis.

3 gh-level aminoglycoside-resistant E faecalis infective endocarditis.

4 rted in the literature, mainly as a cause of infective endocarditis.

5 total cohort of 2760 patients with definite infective endocarditis.

6 ely central mechanism in the pathogenesis of infective endocarditis.

7 coccus oralis is a leading cause of subacute infective endocarditis.

8 population, and a leading causative agent of infective endocarditis.

9 lure (HF) is the most common complication of infective endocarditis.

10 is an important step in the pathogenesis of infective endocarditis.

11 studied 56 patients with definite left-sided infective endocarditis.

12 of the life-threatening endovascular disease infective endocarditis.

13 eport the first case of KPLA associated with infective endocarditis.

14 ent of human dental caries and, at times, of infective endocarditis.

15 ptococcus sanguinis is an important cause of infective endocarditis.

16 platelets contributes to the pathogenesis of infective endocarditis.

17 n was essential for the development of early infective endocarditis.

18 plex decision about surgical intervention in infective endocarditis.

19 s was on bacterial species reported to cause infective endocarditis.

20 minant of the bacterium in the initiation of infective endocarditis.

21 ns group streptococcal species implicated in infective endocarditis.

22 temcomitans is implicated in the etiology of infective endocarditis.

23 iagnostic procedures really are the cause of infective endocarditis.

24 a greater threat for individuals at risk for infective endocarditis.

25 odontitis and extraoral infections including infective endocarditis.

26 s and subsequent management of patients with infective endocarditis.

27 ith the highest risk of adverse outcome from infective endocarditis.

28 nth mortality among patients with left-sided infective endocarditis.

29 t from national and international experts on infective endocarditis.

30 present in 556 (20.1%) of 2670 patients with infective endocarditis.

31 ive and prospective studies of prevention of infective endocarditis.

32 an increased lifetime risk of acquisition of infective endocarditis.

33 important for cariogenesis, bacteremia, and infective endocarditis.

34 diography in the diagnosis and management of infective endocarditis.

35 may be an important virulence determinant of infective endocarditis.

36 ains were observed by using the rat model of infective endocarditis.

37 s can also cause systemic disease, including infective endocarditis.

38 endocarditis and in-hospital mortality after infective endocarditis.

39 herapy in a therapeutic model of established infective endocarditis.

40 tulated central event in the pathogenesis of infective endocarditis.

41 n of causal agents in blood culture-negative infective endocarditis.

42 y play a central role in the pathogenesis of infective endocarditis.

43 to assist in the diagnosis and management of infective endocarditis.

44 rhusiopathiae septic arthritis and possible infective endocarditis.

45 volutionized the diagnosis and management of infective endocarditis.

46 ted major interaction in the pathogenesis of infective endocarditis.

47 tant virulence factor for the development of infective endocarditis.

48 trioventricular block and was diagnosed with infective endocarditis.

49 sed central mechanism in the pathogenesis of infective endocarditis.

50 t virulence mechanism in the pathogenesis of infective endocarditis.

51 icantly associated with an increased risk of infective endocarditis.

52 ic disease and are known causative agents of infective endocarditis.

53 ary tract infections (UTIs), bacteremia, and infective endocarditis.

54 ith C. burnetii can cause a life-threatening infective endocarditis.

55 with Streptococcus mutans and virulence for infective endocarditis.

56 sociated permease A [BepA]), as important in infective endocarditis.

57 attack, recurrent acute rheumatic fever, and infective endocarditis.

58 Infective endocarditis.

59 of the many bacterial species implicated in infective endocarditis.

60 h to advance the understanding of left-sided infective endocarditis.

61 re complications of Streptococcus agalactiae infective endocarditis.

62 foci of infection, and no clinical signs of infective endocarditis.

63 colonizes teeth and is an important cause of infective endocarditis.

64 r ~5.7 x enhancement in imaging of S. aureus infective endocarditis.

65 eptococcus sanguinis is a causative agent of infective endocarditis.

66 iction of the embolism risk in patients with infective endocarditis.

67 tor of embolic events (EEs) in patients with infective endocarditis.

68 igens enhanced disease severity as tested by infective endocarditis.

69 ignificant negative impact on the outcome of infective endocarditis.

70 olic risk (ER) at admission of patients with infective endocarditis.

71 (3.49/1000 patient-years), and 20 (0.7%) had infective endocarditis (3.65/1000 patient-years).

72 (6 patients), septic arthritis (1 patient), infective endocarditis (4 patients), and death (2 patien

73 h infective endocarditis, 66 patients (54%); infective endocarditis, 46 patients (38%; 15 with bicusp

74 e: congenital malformation unassociated with infective endocarditis, 66 patients (54%); infective end

75 Streptococcus sanguinisis a leading cause of infective endocarditis, a life-threatening infection of

76 ponses to vancomycin therapy in experimental infective endocarditis, a prototypical biofilm model.

77 It is also one of the most common agents of infective endocarditis, a serious endovascular infection

78 us arteriosus, or pulmonic stenosis have had infective endocarditis after surgery.

79 The incidence of infective endocarditis after surgical repair of congenit

80 nal Registry included patients with definite infective endocarditis after TAVR from 47 centers from E

81 ssociated with higher risk of progressing to infective endocarditis after TAVR was younger age (78.9

82 acteristics and outcomes of patients who had infective endocarditis after undergoing transcatheter ao

83 contribute significantly to the etiology of infective endocarditis, although recently they have been

84 f Diseases, ninth revision, codes indicating infective endocarditis among admissions of patients <21

85 ive plasmid pCF10) in protective immunity to infective endocarditis, an N-terminal region of Asc10 la

86 the development of the vegetative lesion in infective endocarditis and a thrombotic mechanism to exp

87 i are integral events in the pathogenesis of infective endocarditis and atherosclerosis.

88 cause hospital-acquired infections, such as infective endocarditis and catheter-associated urinary t

89 ycin and imipenem as rescue therapy for MRSA infective endocarditis and complicated bacteremia.

90 anguinis class Ib RNR in an animal model for infective endocarditis and establishing whether the mang

91 Streptococcus sanguinis is a cause of infective endocarditis and has been shown to require a m

92 Infective endocarditis and in-hospital mortality after i

93 er aortic valve replacement for incidence of infective endocarditis and infective endocarditis for in

94 Of 4075 patients with infective endocarditis and known HF status enrolled, 135

95 associated with systemic diseases, including infective endocarditis and neutropenic bacteremia.

96 sent article reviews the challenges posed by infective endocarditis and outlines current and future s

97 by viridans group streptococci can result in infective endocarditis and possibly atherosclerosis; how

98 ificant for both individuals at high risk of infective endocarditis and those at lower risk.

99 challenge in a prophylactic model of rabbit infective endocarditis, and enhance the efficacy of vanc

100 al effect on the interpretation of trends in infective endocarditis, and recent studies have proposed

101 s has become an increasingly common cause of infective endocarditis, and the microbiology of nosocomi

102 stroke, peripheral embolism, heart failure, infective endocarditis, and the need for valve replaceme

103 ylaxis recommendations for the prevention of infective endocarditis are based in part on studies of b

104 in diagnosis, microbiology, and treatment of infective endocarditis are described, and case definitio

105 ntimicrobial guidelines for the treatment of infective endocarditis are readily available, including

106 The challenges posed by infective endocarditis are significant.

107 is is recommended, the true risk factors for infective endocarditis are unclear.

108 We compared the incidence of infective endocarditis before and after the introduction

109 The risk for embolism during infective endocarditis can be quantified at admission us

110 coccus bovis causes 24% of all streptococcal infective endocarditis cases.

111 Infective endocarditis caused by non-HACEK (species othe

112 thus has promise as a vaccinogen to control infective endocarditis caused by oral streptococci.

113 In this cohort of patients with infective endocarditis complicated by HF, severity of HF

114 Diagnosis of infective endocarditis confirmed by hospital or autopsy

115 Infective endocarditis continues to pose major challenge

116 tococci (VS) are primary etiologic agents of infective endocarditis, despite being part of the normal

117 Pathogenic mechanisms in infective endocarditis, disseminated intravascular coagu

118 by doxorubicin plus cyclophosphamide group), infective endocarditis (docetaxel plus bevacizumab follo

119 play a role in protection from experimental infective endocarditis due to E. faecalis and may have i

120 Infective endocarditis due to vancomycin-resistant (VR)

121 binations for treating Enterococcus faecalis infective endocarditis (EFIE).

122 ensis, an opportunistic pathogen that causes infective endocarditis, encodes an Isd system.

123 (95% CI, 10.4%-19.2%) of patients during the infective endocarditis episode.

124 atment does not seem to be a risk factor for infective endocarditis, even in patients with valvular a

125 antibiotic prophylaxis for the prevention of infective endocarditis fell substantially after introduc

126 for incidence of infective endocarditis and infective endocarditis for in-hospital mortality.

127 educing gentamicin treatment in enterococcal infective endocarditis from 4 to 6 weeks to only 2 weeks

128 ts with definite native- or prosthetic-valve infective endocarditis from 61 centers in 28 countries b

129 t of 1345 consecutive episodes of left-sided infective endocarditis from 8 centers in Spain.

130 ics for patients with a primary diagnosis of infective endocarditis from Jan 1, 2000, to March 31, 20

131 The epidemiology of infective endocarditis has become more complex with toda

132 The diagnosis of infective endocarditis has been notoriously difficult.

133 procedures in patients at risk of developing infective endocarditis has historically been the focus o

134 ve fallen substantially and the incidence of infective endocarditis has increased significantly in En

135 The role of valve surgery in left-sided infective endocarditis has not been evaluated in randomi

136 Acute brain embolization (ABE) in left-sided infective endocarditis has significant implications for

137 Prophylaxis and treatment guidelines for infective endocarditis have changed substantially over t

138 The clinical variability and complexity in infective endocarditis, however, dictate that these reco

139 atus, and dental procedures in patients with infective endocarditis (IE) according to whether the IE-

140 e incidence, clinical course, and outcome of infective endocarditis (IE) after TPV implant.

141 characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic v

142 y virus (HIV) infection and other factors on infective endocarditis (IE) among injection drug users (

143 to identify patients with increased risk of infective endocarditis (IE) among patients with Enteroco

144 The reported incidence of infective endocarditis (IE) among patients with SAB vari

145 e Staphylococcus aureus (MSSA) isolates from infective endocarditis (IE) and soft tissue infections (

146 Data on early determinants of outcome in infective endocarditis (IE) are limited.

147 Use of surgery for the treatment of infective endocarditis (IE) as related to surgical indic

148 The risks of infective endocarditis (IE) associated with various cond

149 ography plays a key role in the diagnosis of infective endocarditis (IE) but can be inconclusive in p

150 nd prophylaxis were compared in experimental infective endocarditis (IE) caused by an isogenic Staphy

151 of Cardiology and American Heart Association infective endocarditis (IE) guideline update, antibiotic

152 art Association guidelines for prevention of infective endocarditis (IE) in 2007 reduced the groups o

153 population-based epidemiological changes in infective endocarditis (IE) in Europe.

154 The diagnosis of infective endocarditis (IE) in prosthetic valves and int

155 his study was to evaluate temporal trends in infective endocarditis (IE) incidence and clinical chara

156 Infective endocarditis (IE) is a rare disease with poor

157 Infective endocarditis (IE) is a serious complication of

158 Early diagnosis of infective endocarditis (IE) is based on the yielding of

159 or and treating the portal of entry (POE) of infective endocarditis (IE) is important, but published

160 Gram-negative bacilli causing infective endocarditis (IE) is rare, even in intravenous

161 a expression in vitro and in an experimental infective endocarditis (IE) model using flow cytometry.

162 ctin binding in vitro and in an experimental infective endocarditis (IE) model using parental strains

163 Infective endocarditis (IE) mostly occurs after spontane

164 Association published updated guidelines for infective endocarditis (IE) prevention in 2007 that mark

165 he timing of cardiac surgery after stroke in infective endocarditis (IE) remains controversial.

166 rvational studies showed that the profile of infective endocarditis (IE) significantly changed over t

167 ct of vancomycin MIC on left-sided S. aureus infective endocarditis (IE) treated with cloxacillin.

168 biotic prophylaxis (AP) for those at risk of infective endocarditis (IE) undergoing dental procedures

169 g, and the number of episodes complicated by infective endocarditis (IE) varies.

170 The diagnosis of infective endocarditis (IE) was established by using the

171 t in 42 patients (41%), clinical evidence of infective endocarditis (IE) was rare (7%).

172 staphylococci (CNS) are important causes of infective endocarditis (IE), but their microbiological p

173 c valve abnormalities have increased risk of infective endocarditis (IE), it is unknown whether these

174 ment in surgical mortality for patients with infective endocarditis (IE), presumably because of impro

175 from methicillin-resistant S. aureus (MRSA) infective endocarditis (IE), we characterized patients w

176 Substantial infective endocarditis (IE)-related morbidity and mortal

177 tal plaque and important agents of bacterial infective endocarditis (IE).

178 ntibiotic prophylaxis in patients at risk of infective endocarditis (IE).

179 nse against endovascular infections, such as infective endocarditis (IE).

180 tect against endovascular infections such as infective endocarditis (IE).

181 with more extensive disease in experimental infective endocarditis (IE).

182 to the understanding of the pathogenesis of infective endocarditis (IE).

183 assess the characteristics of children with infective endocarditis in a large national sample.

184 tients presenting with definite diagnoses of infective endocarditis in a multicenter observational co

185 e are effects of gC1qR blockade on S. aureus infective endocarditis in addition to blocking gC1qR-med

186 um is also a cardiovascular pathogen causing infective endocarditis in children and adults.

187 eases of the skeletal system in children and infective endocarditis in children and adults.

188 Infective endocarditis in children is rare, and most rep

189 is versus no prophylaxis on the incidence of infective endocarditis in England.

190 , and is also implicated in causing subacute infective endocarditis in humans.

191 counts for a high percentage of all cases of infective endocarditis in many regions of the world.

192 of antibiotic prophylaxis for prevention of infective endocarditis in March, 2008.

193 cus is an increasing cause of bacteremia and infective endocarditis in the elderly.

194 fy trends in the incidence and etiologies of infective endocarditis in the United States.

195 e regarding procedure-related bacteremia and infective endocarditis, in vitro susceptibility data of

196 rting in March, 2008, the number of cases of infective endocarditis increased significantly above the

197 development of large caseous lesions, and in infective endocarditis, increases the size of pathognomo

198 Infective endocarditis is a complex disease, and patient

199 Infective endocarditis is a complex disease, with many h

200 Infective endocarditis is a life-threatening disease wit

201 Infective endocarditis is a potentially lethal disease t

202 Infective endocarditis is a typical biofilm-associated i

203 mon cause of nosocomial infections, of which infective endocarditis is associated with substantial mo

204 important interaction in the pathogenesis of infective endocarditis is attachment of the organisms to

205 carditis, and the microbiology of nosocomial infective endocarditis is changing.

206 Infective endocarditis is defined by a focus of infectio

207 Infective endocarditis is life-threatening; identificati

208 udy suggest that valve surgery in left-sided infective endocarditis is not associated with a survival

209 Infective endocarditis is one of the most common clinica

210 Although antibiotic prophylaxis against infective endocarditis is recommended, the true risk fac

211 Biofilms on native heart valves (infective endocarditis) is a life-threatening disease as

212 nagement-based approach for the treatment of infective endocarditis, leading to a strong reduction of

213 taphylococcus aureus left-sided native valve infective endocarditis (LNVIE) has higher complication a

214 t only an extremely small number of cases of infective endocarditis might be prevented by antibiotic

215 n of empA also resulted in attenuation in an infective endocarditis model (P = 0.0088).

216 ore resistant to vancomycin treatment in the infective endocarditis model than a RB comparator strain

217 th their respective parental strains, in the infective endocarditis model.

218 athogenesis of Enterococcus faecium in a rat infective endocarditis model.

219 ry genes in vivo was carried out using a rat infective endocarditis model.

220 ere compiled on tachyarrhythmias, pregnancy, infective endocarditis, noncardiac surgery and the multi

221 Persons with community-acquired infective endocarditis not associated with intravenous d

222 pose the highest risk for bad outcome should infective endocarditis occur and only for dental procedu

223 A total of 250 cases of infective endocarditis occurred in 20006 patients after

224 Infective endocarditis occurs worldwide, and is defined

225 No infective endocarditis or aortic dissection was found.

226 There were no instances of infective endocarditis or thromboembolic complications e

227 ults in serious secondary infections such as infective endocarditis, osteomyelitis, and septic arthri

228 se of bacteraemia, which frequently leads to infective endocarditis, osteomyelitis, septic arthritis

229 of diagnosis, microbiology, and treatment of infective endocarditis, particularly as they are influen

230 ocarditis has historically been the focus of infective endocarditis prevention.

231 (2) Infective endocarditis prophylaxis for dental procedures

232 ges are intended to define more clearly when infective endocarditis prophylaxis is or is not recommen

233 ng the following search terms: endocarditis, infective endocarditis, prophylaxis, prevention, antibio

234 Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unresolved.

235 ganisms is a recognized but unusual cause of infective endocarditis, responsible for approximately 3%

236 of the most common microorganisms that cause infective endocarditis, results of prophylactic studies

237 n vivo during infections in rabbit models of infective endocarditis, sepsis, and pneumonia.

238 auses life-threatening infections, including infective endocarditis, sepsis, and pneumonia.

239 All patients with suspected infective endocarditis should undergo transthoracic echo

240 To identify virulence factors for infective endocarditis, signature-tagged mutagenesis (ST

241 antibiotic prophylaxis and the incidence of infective endocarditis since the introduction of these g

242 During pathogenesis of infective endocarditis, Staphylococcus aureus adherence

243 red proteins may play a role in S. sanguinis infective endocarditis, strategies designed to interfere

244 ill develop serious complications, including infective endocarditis, sudden cardiac death, and severe

245 bstantial number of patients with left-sided infective endocarditis, suggesting that the incidence of

246 The characteristic lesion seen with infective endocarditis, termed "the vegetation," is comp

247 eart Association (AHA) for the prevention of infective endocarditis that were last published in 1997.

248 neurological complications in patients with infective endocarditis, the risk factors for their devel

249 nuing shift in the epidemiology of pediatric infective endocarditis toward a higher proportion of chi

250 comes in patients with Enterococcus faecalis infective endocarditis treated in the years before and a

251 nical characteristics of HF in patients with infective endocarditis, use of surgical therapy, and the

252 s after surgery, the cumulative incidence of infective endocarditis was 1.3% for tetralogy of Fallot,

253 Median time from TAVR to infective endocarditis was 5.3 months (interquartile ran

254 ement of each cell wall-anchored protein for infective endocarditis was assessed in the rabbit model.

255 Health care-associated infective endocarditis was present in 52.8% (95% CI, 46.

256 Association guidelines for the prevention of infective endocarditis was recently published in their j

257 This increase in the incidence of infective endocarditis was significant for both individu

258 State, the overall standardized incidence of infective endocarditis was stable from 1998 through 2013

259 of aminoglycosides, the Danish guidelines on infective endocarditis were changed in January 2007, red

260 l (8/8) patients with blood culture-positive infective endocarditis were determined to be positive by

261 of 546 consecutive patients with left-sided infective endocarditis were included.

262 eir expertise in prevention and treatment of infective endocarditis, with liaison members representin

263 Few cases of infective endocarditis would be preventable with antibio